PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
Small Molecule
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
Gene Therapy
DB-XX1* Balance Dysfunction
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
DB-XX1* Balance Dysfunction
Gene Therapy
DB-XX3* Monogenic Hearing Loss: Gene 2
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
DB-XX3* Monogenic Hearing Loss: Gene 2
Gene Therapy
DB-XX4* Monogenic Hearing Loss: Gene 3
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
DB-XX4* Monogenic Hearing Loss: Gene 3
Gene Therapy
DB-XX5* Tinnitus; Auditory Neuropathy
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
DB-XX5* Tinnitus; Auditory Neuropathy
Biologic
Novel target ID Noise, Age, Tinnitus, Balance
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
Novel target ID Noise, Age, Tinnitus, Balance
Undisclosed

Small Molecules:

PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I

Gene Therapeutics:

PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
DB-XX1* Balance Dysfunction
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
DB-XX1* Balance Dysfunction
DB-XX3* Monogenic Hearing Loss: Gene 2
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
DB-XX3* Monogenic Hearing Loss: Gene 2
DB-XX4* Monogenic Hearing Loss: Gene 3
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
DB-XX4* Monogenic Hearing Loss: Gene 3

Biologics:

PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
DB-XX5* Tinnitus; Auditory Neuropathy
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
DB-XX5* Tinnitus; Auditory Neuropathy

Undisclosed:

PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
Novel target ID Noise, Age, Tinnitus, Balance
PROGRAM
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
Novel target ID Noise, Age, Tinnitus, Balance

* Currently included in the Decibel Regeneron collaboration. Decibel retains worldwide development and commercial rights. Regeneron co-funds the development of collaboration programs and receives tiered royalties based on net sales.